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This thesis reports on the clinical value and potential of 11C-choline PET/CT in 
recurrent prostate cancer imaging. The results of the clinical studies showed that 11C-choline 
PET/CT has a high overall sensitivity in detection of a local recurrence in the prostate after 
EBRT on a patient based analysis. Our results suggest that 11C-choline PET/CT could be 
useful for the selection of patients with a biochemical recurrence after radiotherapy for 
salvage cryoablation of the prostate. By accurately identifying the patients with nodal or 
distant metastases, 11C-choline PET/CT impacts the therapeutic decision-making for those 
who would not benefit from local salvage treatment. 
It was shown that total serum PSA and PSA velocity have significant effect on the 
detection rates of 11C-choline PET/CT in men with a biochemical recurrence after both 
radical prostatectomy and EBRT. Also a negative PET/CT correlates with a higher disease 
specific survival and a lower treatment rate in men with a biochemical recurrence after 
radical prostatectomy. 
At the same time the accuracy of 11C-choline PET/CT for the intraprostatic tumor 
characterization and localization in patients with recurrent prostate cancer after EBRT is too 
low to use this imaging technique routinely for this indication. It means that 11C-choline 
PET/CT is not able to improve the localization of recurrent small focal prostate tumors. So it 
cannot contribute to the ‘image-guided focal therapy’ application in recurrent prostate cancer 
after EBRT. 
Most tracers which are currently used for molecular imaging of the prostate cancer like 
choline in our studies are not (prostate) cancer-specific. The main goal now is the 
development of radiopharmaceuticals targeting tumour specific antigens and receptors. The 
adequacy of prostate-specific membrane antigen (PSMA), epithelial cell adhesion 
molecule (EpCAM), vascular endothelial growth factor (VEGF) and gastrin-releasing peptide 
receptor (GRPR) for targeted imaging is analyzed in this dissertation. The results suggest 
that PSMA, EpCAM and VEGF can be used for targeted imaging of locally recurrent prostate 
cancer based on their high tumour distinctiveness. PSMA showed the best characteristics for 
imaging of recurrent prostate cancer.  
PSMA or glutamate carboxypeptidase II is an enzyme that in humans is encoded by 
the FOLH1 (folate hydrolase 1) gene. PSMA is strongly expressed in the human prostate, 
being a hundredfold greater than the expression in most other tissues. It is upregulated in 
expression in prostate cancer, with increase of 8- to 12-fold over the noncancerous prostate. 
PSMA is the target of an approved imaging agent for prostate cancer, capromabpentide, 
ProstaScint
®
. However, for routine use in clinical practice, the sensitivity of ProstaScint
®
 is 
not high enough, because the antibody targets the intracellular epitope of PSMA, thereby 
probably targeting only damaged or necrotic/apoptotic cells [1]. Several second-generation 
antibodies and low-molecular-weight ligands for imaging and therapy are being developed, 
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but most studies are still in a preclinical phase [1]. 68Ga-PSMA PET/CT already showed 
significantly higher detection rate of lesions in patients with recurrent prostate cancer 
compared to 18F-fluoromethylcholine PET/CT even at low PSA levels [2]. 
Recent developments in MRI have improved the diagnostic process of prostate 
cancer. Multiparametric MRI is considered a promising technique to improve the detection 
and staging of prostate cancer and its application has emerged during last few years. The 
integration of diffusion weighted imaging (DWI), dynamic contrast enhanced (DCE) imaging, 
and spectroscopic (functional) imaging in combination has allowed radiologists to better 
identify areas of benign and potentially malignant disease. There are ongoing efforts to 
combine MR methods in multiparametric formats to improve the performance characteristics 
of the detection and localization of prostate cancer. Future additions may include diffusion 
tensor imaging, multi-component diffusion analysis, MR elastography, or new spectroscopic 
methods, which are currently in pre-clinical investigation [3]. 
For molecular imaging PET/CT is now widely available. It provides both anatomical 
and metabolic information. PET/MRI is another hybrid imaging modality, which already 
received great attention not only in its emerging clinical applications but also in the 
preclinical ﬁeld. Research studies are actively conducted at the moment to understand 
benefits of the new PET/MRI diagnostic method. First clear advantage is lower radiation 
exposure using PET/MRI. According to several studies PET/MRI may increase the accuracy 
using simultaneous acquisition of high-resolution morphologic and functional data. In the 
comparison study PET/MRI was able to accurately detect recurrent prostate cancer clarifying 
unclear findings by PET/CT [4]. Studies with appropriate radiotracers targeting the specific 
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